Cd55-interaction partners and the uses thereof

Abstract

The invention relates to the use of a binding member that binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody that binds to SCR1 and SCR2 of CD55 and neutralizing CD55 and making cancer cells susceptible to complement-mediated attack.

What is claimed is: 
     
         1 . A method of treating cancer in a human subject, said method comprising administering a therapeutically effective amount of
 (i) a naked antibody or fragment thereof which specifically binds to short consensus repeat 1 (SCR1) and short consensus repeat 2 (SCR2) of CD55 or   (ii) a nucleic acid molecule encoding said antibody or fragment thereof to a human subject in need thereof, wherein said human subject has a cancer comprising CD55-expressing cancer cells and wherein said cancer is not lung cancer, thereby treating cancer in a human subject.   
     
     
         2 . The method according to  claim 1 , wherein the cancer is selected from the group consisting of a sarcoma, carcinoma, lymphoma, glioma, retinoblastoma and leukaemia. 
     
     
         3 . The method according to  claim 1 , wherein the cancer is selected from the group consisting of an osteogenic sarcoma, soft tissue sarcoma, breast cancer, bladder cancer, thyroid cancer, prostate cancer, colon cancer, rectum cancer, pancreas cancer, stomach cancer, liver cancer, uterine cancer, cervical cancer, ovarian cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, neuroblastoma, melanoma, myeloma, Wilms tumor, acute lymphoblastic leukaemia and acute myeloblastic leukaemia. 
     
     
         4 . The method according to  claim 1 , wherein said antibody or fragment thereof binds to SCR1 amino acids 83-93 (corresponding to amino acids 1-11 of SEQ ID NO:7), and SCR2 amino acids 101-112 and amino acids 145-157 (corresponding to amino acids 19-30 of SEQ ID NO:7 and amino acids 8-20 of SEQ ID NO:10 respectively). 
     
     
         5 . The method according to  claim 1 , wherein
 (i) said antibody or fragment thereof comprises one or more CDRs of the antibody produced by the hybridoma deposited at ATCC under accession number HB9173, or   (ii) said antibody or fragment thereof is antibody 791T/36 produced by the hybridoma deposited at ATCC under accession number HB9173 or a fragment thereof.   
     
     
         6 . The method according to  claim 1 , wherein said antibody or fragment thereof comprises at least one human constant region. 
     
     
         7 . The method according to  claim 1 , further comprising co-administering a therapeutically effective amount of one or more active agents selected from the group consisting of a chemotherapeutic agent, a pain relief drug, a further antibody, an anti-emetic, Doxorubicin, taxol, 5-Fluorouracil (5 FU), Leucovorin, Irinotecan, Mitomycin C, Oxaliplatin, Raltitrexed, Tamoxifen, Cisplatin, aspirin, paracetamol, ibuprofen, and ketoprofen. 
     
     
         8 . The method according to  claim 7 , wherein the further antibody is selected from the group consisting of an anti-CD20 antibody, an anti-VEGF antibody, an anti-CD171A antibody, an anti-EGFR antibody, and an anti-HER2 antibody. 
     
     
         9 . A method of neutralising CD55 activity on CD55-expressing cancer cells in a human subject, said method comprising administering an effective amount of
 (i) a naked antibody or fragment thereof which specifically binds to SCR1 and SCR2 of CD55 or   (ii) a nucleic acid molecule encoding said antibody or fragment thereof   to a human subject having a cancer comprising CD55-expressing cancer cells, wherein said cancer is not lung cancer, thereby neutralising activity CD55 on CD55-expressing cancer cells in a human subject.   
     
     
         10 . The method according to  claim 9 , wherein the cancer is selected from the group consisting of a sarcoma, carcinoma, lymphoma, glioma, retinoblastoma and leukaemia. 
     
     
         11 . The method according to  claim 9 , wherein the cancer is selected from the group consisting of an osteogenic sarcoma, soft tissue sarcoma, breast cancer, bladder cancer, thyroid cancer, prostate cancer, colon cancer, rectum cancer, pancreas cancer, stomach cancer, liver cancer, uterine cancer, cervical cancer, ovarian cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, neuroblastoma, melanoma, myeloma, Wilms tumor, acute lymphoblastic leukaemia and acute myeloblastic leukaemia. 
     
     
         12 . The method according to  claim 9 , wherein said antibody or fragment thereof binds to SCR1 amino acids 83-93 (corresponding to amino acids 1-11 of SEQ ID NO:7), and SCR2 amino acids 101-112 and amino acids 145-157 (corresponding to amino acids 19-30 of SEQ ID NO:7 and amino acids 8-20 of SEQ ID NO:10 respectively). 
     
     
         13 . The method according to  claim 9 , wherein
 (i) said antibody or fragment thereof comprises one or more CDRs of the antibody produced by the hybridoma deposited at ATCC under accession number HB9173, or   (ii) said antibody or fragment thereof is antibody 791T/36 produced by the hybridoma deposited at ATCC under accession number HB9173 or a fragment thereof.   
     
     
         14 . The method according to  claim 9 , wherein said antibody or fragment thereof comprises at least one human constant region. 
     
     
         15 . A method of enhancing complement deposition on CD55-expressing cancer cells in a human subject, said method comprising administering an effective amount of
 (i) a naked antibody or fragment thereof which specifically binds to SCR1 and SCR2 of CD55 or   (ii) a nucleic acid molecule encoding said antibody or fragment thereof   to a human subject having a cancer comprising CD55-expressing cancer cells, wherein said cancer is not lung cancer, thereby enhancing complement deposition on CD55-expressing cancer cells in a human subject.   
     
     
         16 . The method according to  claim 15 , wherein the cancer is selected from the group consisting of a sarcoma, carcinoma, lymphoma, glioma, retinoblastoma and leukaemia. 
     
     
         17 . The method according to  claim 15 , wherein the cancer is selected from the group consisting of an osteogenic sarcoma, soft tissue sarcoma, breast cancer, bladder cancer, thyroid cancer, prostate cancer, colon cancer, rectum cancer, pancreas cancer, stomach cancer, liver cancer, uterine cancer, cervical cancer, ovarian cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, neuroblastoma, melanoma, myeloma, Wilms tumor, acute lymphoblastic leukaemia and acute myeloblastic leukaemia. 
     
     
         18 . The method according to  claim 15 , wherein said antibody or fragment thereof binds to SCR1 amino acids 83-93 (corresponding to amino acids 1-11 of SEQ ID NO:7), and SCR2 amino acids 101-112 and amino acids 145-157 (corresponding to amino acids 19-30 of SEQ ID NO:7 and amino acids 8-20 of SEQ ID NO:10 respectively). 
     
     
         19 . The method according to  claim 15 , wherein:
 (i) said antibody or fragment thereof comprises one or more CDRs of the antibody produced by the hybridoma deposited at ATCC under accession number HB9173, or   (ii) said antibody of fragment thereof is antibody 791T/36 produced by the hybridoma deposited at ATCC under accession number HB9173 or a fragment thereof.   
     
     
         20 . The method according to  claim 15 , wherein said antibody or fragment thereof comprises at least one human constant region.